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AbstrAct:
Recent clinical evidence revealed that the use of beta-blockers such as propranolol, 
prior to diagnosis or concurrently with chemotherapy, could increase relapse-free and 
overall survival in breast cancer patients. We therefore hypothesized that propranolol 
may be able to increase the efficacy of chemotherapy either through direct effects on 
cancer cells or via anti-angiogenic mechanisms. In vitro proliferation assay showed 
that propranolol (from 50-100 μM) induces dose-dependent anti-proliferative effects 
in a panel of 9 human cancer and “normal” cell lines. Matrigel assays revealed that 
propranolol  displays  potent  anti-angiogenic  properties  at  non-toxic  concentrations 
(<50  μM)  but  exert  no  vascular-disrupting  activity.  Combining  chemotherapeutic 
drugs,  such  as  5-fluorouracil  (5-FU)  or  paclitaxel,  with  propranolol  at  the  lowest 
effective  concentration  resulted  in  synergistic,  additive  or  antagonistic  effects  on 
cell proliferation in vitro depending on the cell type and the dose of chemotherapy 
used. Interestingly, breast cancer and vascular endothelial cells were among the most 
responsive to these combinations. Furthermore, Matrigel assays indicated that low 
concentrations of propranolol (10 – 50 μM) potentiated the anti-angiogenic effects 
of 5-FU and paclitaxel. Using an orthotopic xenograft model of triple-negative breast 
cancer, based on injection of luciferase-expressing MDA-MB-231 cells in the mammary 
fat pad of nude mice, we showed that propranolol, when used alone, induced only 
transient anti-tumor effects, if at all, and did not increase median survival. However, 
the combination of propranolol with chemotherapy resulted in more profound and 
sustained anti-tumor effects and significantly increased the survival benefits induced 
by chemotherapy alone (+19% and +79% in median survival for the combination as 
compared with 5-FU alone and paclitaxel alone, respectively; p<0.05). Collectively 
our results show that propranolol can potentiate the anti-angiogenic effects and anti-
tumor efficacy of chemotherapy. The current study, together with retrospective clinical 
data, strongly suggests that the use of propranolol concurrently with chemotherapy 
may  improve  the  outcome  of  breast  cancer  patients,  thus  providing  a  strong 
rationale for the evaluation of this drug combination in prospective clinical studies.Oncotarget 2011; 2:  797 - 809 798 www.impactjournals.com/oncotarget
INtrODUctION
The costs associated with drug development are 
rising so dramatically that cheaper, faster and more 
effective strategies to identify new compounds and 
implement them successfully in the clinic are desperately 
needed  [1].  In  the  current  financial  and  economical 
context, drug repositioning, which consists of using 
already approved drugs for new medical indications, is 
gaining increasing interest as an alternative strategy for 
drug development [2-4]. By using drugs with well-known 
toxicity and pharmacokinetics profiles, this strategy can 
remove several years, substantial risks and costs from the 
pathway to the clinic. For instance, the recent discovery of 
the efficacy of propranolol -a non-selective β-adrenergic 
receptor  (β-AR)  antagonist  commonly  used  for  the 
treatment of hypertension- in treating severe infantile 
haemangioma has revolutionized the management of this 
pathology in 2 years [5, 6]. Although the first evidence 
for a role of β-ARs in cancer progression was provided 
more than 20 years ago [7], the serendipitous observation 
of the efficacy of propranolol in treating haemangiomas 
has renewed interest in exploring the anti-angiogenic and 
anti-cancer  properties  of  β-AR  antagonists  (also  called 
β-blockers). 
A number of in vitro studies have demonstrated the 
anti-proliferative, anti-migratory and cytotoxic properties 
of propranolol, particularly against lung adenocarcinoma 
[7, 8], colon carcinoma [9], breast carcinoma [10], 
nasopharyngeal carcinoma [11], ovarian cancer [12], 
pancreatic cancer [13-15] and gastric cancer cells 
[16]. Propranolol was also found to exert potent anti-
angiogenic effects in vitro through direct mechanisms 
on vascular endothelial cells [17, 18] and by decreasing 
pro-angiogenic signaling in both stromal [19] and cancer 
cells [11, 20-23]. Some of these promising anti-cancer 
properties  have  been  confirmed  in vivo using different 
animal models of human cancers. Propranolol was thus 
found to exert potent cancer preventive effects in models 
of chemically-induced lung and pancreatic cancers [24, 
25]. Furthermore, innovative pre-clinical models of breast 
and ovarian cancer showed that propranolol was able 
to  specifically  inhibit  stress-induced  tumor  growth  and 
metastatic spread through anti-angiogenic and immuno-
stimulatory mechanisms [26, 27]. 
Over the past 12 months, emerging clinical data 
have  further  strengthened  the  potential  benefits  of 
β-AR  antagonists  in  cancer  patients  [28,  29].  Three 
retrospective clinical studies revealed that the use of β-AR 
antagonists, prior to diagnosis and/or concomitantly with 
chemotherapy, was associated with increased survival 
and/or decreased metastatic spread and incidence of tumor 
recurrence in breast cancer patients [30-32]. Different 
molecular mechanisms have been proposed to explain such 
benefits of β-AR antagonists in breast cancer patients [28, 
29], focusing on the anti-metastatic properties of β-AR 
antagonists  alone.  Here,  we  hypothesized  for  the  first 
time that β-AR antagonists, and propranolol in particular, 
may be able to increase the efficacy of chemotherapy by 
potentiating the anti-proliferative and/or anti-angiogenic 
effects of chemotherapeutic drugs. We thus proposed 
to investigate the combination of propranolol and 
chemotherapy on cell proliferation and angiogenesis in 
vitro and on tumor growth inhibition and survival in vivo 
using an orthotopic model of triple-negative breast cancer.
Figure 1: In vitro anti-proliferative properties of 
propranolol. Growth inhibition assay performed on a panel 
of  human  cell  lines  using Alamar  Blue  or  MTT  after  72  h 
incubation with a range of concentrations of propranolol. Three 
breast adenocarcinoma cell lines (MCF-7, MDA-MB-231 and 
SKBR3) and a breast epithelial cell line (HBL-100) were first 
used (A) and then a neuroblastoma (SK-N-SH), a non-small cell 
lung carcinoma (A549), a glioblastoma (U87) and two vascular 
endothelial cell lines (HMEC-1 and BMH29L) were used (B). 
Points, % of cell proliferation as compared to untreated control 
cells, means of at least three individual experiments; bars, SE; 
log scale for x axis. C) Histogram representation of the molar 
concentration of propranolol required to inhibit 50% of cell 
proliferation after 72h drug incubation (IC50) for all tested cell 
lines. Columns, means of at least three individual experiments; 
bars, SE.
A
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rEsULts
Propranolol exerts dose-dependent anti-
proliferative and anti-angiogenic effects in vitro 
To investigate the anti-proliferative properties of 
propranolol in vitro a range of human cell lines were used 
and comprised of 6 cancer cell lines originating from breast 
carcinomas (MCF-7, MDA-MB-231 and SKBR3), non-
small cell lung carcinoma (A549), neuroblastoma (SK-N-
SH) and glioblastoma (U87), as well as 3 “normal” cell 
lines including 1 breast epithelial cell line (HBL-100) and 
2 vascular endothelial cell lines (HMEC-1 and BMH29L). 
As shown in Figure 1A & B, propranolol exerts dose-
dependent anti-proliferative effects against all tested 
cell lines. There was however a significant variability in 
sensitivity to propranolol across the different cell lines 
with IC50 values ranging from 100 to 269 μM (Figure 1C). 
The two most sensitive cell lines were breast carcinoma 
cell  line  MCF-7  and  bone  marrow-derived  endothelial 
cell line BMH29L with IC50 values of 100 ± 11 μM and 
106 ± 5 μM, respectively. In contrast, breast epithelial 
cell line HBL-100 and non-small cell lung carcinoma cell 
line A549 were the most resistant to propranolol with IC50 
values of 269 ± 22 μM and 222 ± 21 μM, respectively.
Two  types  of  MatrigelTM assays were used to 
examine both the anti-angiogenic and vascular-
disrupting properties of propranolol in vitro. In 
BMH29L  cells,  propranolol  was  found  to  exert 
potent dose-dependent anti-angiogenic effects 
but have almost no vascular-disrupting activity 
(Figure  2).  The  formation  of  vascular  structures 
was significantly inhibited after 8h incubation with 
low concentrations of propranolol (7, 20 and 38% 
inhibition at 10, 25 and 50 μM, respectively; p<0.01) 
compared to control, and complete angiogenesis 
suppression was observed at high concentrations. 
In contrast, propranolol concentrations of up to 
150  μM  induced  no  significant  disruption  of  pre-
formed vascular structures after 2h drug incubation 
and high concentrations were required to start 
disrupting the vascular network (35% disruption at 
250  μM;  p<0.001).  Similar  results  were  obtained 
with HMEC-1 cells (data not shown) thus confirming 
that propranolol is a potent anti-angiogenic but not 
vascular-disrupting agent.
Figure 2: In vitro anti-angiogenic and 
vascular-disrupting properties of 
propranolol.  A)  Representative  photographs  of 
BMH29L cells in MatrigelTM assays. For the anti-
angiogenesis assay (left panel), cells were treated 
with a range of propranolol concentrations 20 min 
after seeding on MatrigelTM and photographs were 
taken after 8h drug incubation. For the vascular-
disruption assay (right panel),  cells  were  first 
allowed to form capillary-like structures for 6 h 
before drug treatment was initiated and photographs 
were taken after 2h drug incubation. Vascular 
structures were imaged on a Zeiss Axiovert 200M 
using a 5 X objective. Inset, % of inhibition/
disruption as compared to untreated control cells 
(N.S = not statistically significant); Scale bar, 200 
µm.  B)  Dose-dependent  anti-angiogenic  (solid 
line) and vascular-disrupting (broken line) effects 
of propranolol on BMH29L cells. Points, average 
surface occupied by vascular structures in each view 
field, means of at least four individual experiments; 
bars, SE; log scale for x axis.
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Propranolol potentiates the anti-proliferative 
effects of chemotherapy in a cell type-specific and 
dose-dependent manner 
Drug combination studies using growth 
inhibition assay were performed to determine whether 
propranolol can potentiate the anti-proliferative effects 
of chemotherapeutic drugs. The lowest effective 
concentration  of  propranolol  (IC10-IC15)  was  combined 
with a range of concentrations of the pyrimidine analog 
5-fluorouracil  (5-FU)  and  the  microtubule-stabilizing 
agent paclitaxel in the panel of 9 human cell lines. After 
72h drug incubation, cell proliferation was measured by 
Alamar Blue or MTT and combination index (CI) values 
were calculated for all tested drug concentrations based 
on the Chou and Talalay method [33, 34]. The CI theorem 
provides quantitative definition for additive effects (CI = 
1), synergisms (CI<1) and antagonisms (CI>1) in drug 
combinations. The combination of propranolol with 
5-FU resulted in a synergistic, additive or antagonistic 
interaction depending on the dose of 5-FU used and the 
cell type (Figure 3A and Table 1). In all 3 breast cancer cell 
lines and HMEC-1 endothelial cells, this drug combination 
resulted  in  a  slight  antagonism  at  1  μM  5-FU  but  the 
interaction became additive or synergistic with increasing 
concentrations of 5-FU. In BMH29L endothelial cells, the 
interaction between propranolol and 5-FU was synergistic 
at all tested concentrations. In contrast, an antagonistic 
effect was observed at all tested concentrations in HBL-
100 breast epithelial cells. Interestingly, in other types 
of cancer cell lines (i.e. A549, SK-N-SH and U87), the 
combination of propranolol and 5-FU mostly resulted in 
an antagonism (Table 1).
Cell type-specific and dose-dependent effects were 
also observed when combining propranolol and paclitaxel 
(Figure 3B and Table 1). In contrast with the previous 
drug combination, diverse effects were observed in the 
Figure 3: In vitro drug combination study of 
propranolol and chemotherapy on cell proliferation. 
Histogram  representation  of  the  combination  index  (CI)  of 
propranolol in association with 5-fluorouracil (A) or paclitaxel 
(B) on a panel of human cell lines. Growth inhibition assays were 
performed using Alamar Blue or MTT after 72 h incubation with 
a range of chemotherapeutic drug concentrations in presence 
or absence of propranolol at the lowest effective concentration 
(IC15). CI values were determined based on the Chou and Talalay 
method for all tested concentrations of chemotherapeutic drug. 
Columns, means of at least three individual experiments; bars, 
SE.
A
B Paclitaxel
5-fluorouracil
Cell lines
5-Fluorouracil Paclitaxel
1 μM 10 μM 50 μM 5 nM 10 nM 25 nM
MCF-7 1.38  ± 0.16 1.01  ± 0.08 0.89  ± 0.18 1.31  ± 0.07 0.71  ± 0.07 0.5 ± 0.03
MDA-MB-231 1.3 ± 0.18 0.96  ± 0.08 1.05  ± 0.13 1.23  ± 0.08 1.21  ± 0.1 1.38  ± 0.05
SKBR3 1.51  ± 0.87 0.74  ± 0.09 0.82  ± 0.25 0.95  ± 0.26 1.23  ± 0.34 2.32  ± 0.77
HBL-100 1.22  ± 0.44 1.76  ± 0.59 2.82  ± 1.51 1.44  ± 0.26 1.93  ± 0.51 3.18  ± 1.23
HMEC-1 1.34  ± 0.21 1.06  ± 0.14 0.64  ± 0.04 1.08  ± 0.1 0.98  ± 0.07 0.67  ± 0.05
BMH29L 0.83  ± 0.08 0.64  ± 0.08 0.40  ± 0.03 0.85  ± 0.21 0.79  ± 0.2 0.81  ± 0.17
A549 0.92  ± 0.32 1.56  ± 0.47 1.93  ± 0.61 0.73  ± 0.04 1.12  ± 0.41 1.5 ± 0.63
SK-N-SH 1.10  ± 0.43 1.39  ± 0.05 4.58  ± 1.7 0.52  ± 0.06 0.71  ± 0.08 0.70  ± 0.08
U87 6.57  ± 3.39 8.18  ± 2.02 6.6 ± 2.21 3.67  ± 1.31 2.45  ± 0.68 1.69  ± 0.91
table 1: combination index of propranolol and chemotherapeutic drugs in vitro. Growth inhibition assays were performed 
on a panel of 9 human cell lines using Alamar Blue or MTT after 72 h incubation with a range of chemotherapeutic drug concentrations in 
presence or absence of propranolol at the lowest effective concentration (IC15). Combination index values (± SE) were determined based 
on the Chou and Talalay method for all tested concentrations of chemotherapeutic drug. A color code is used to illustrate the different drug 
interactions: synergism (green), additivity (yellow), sub-additivity (orange) and antagonism (red).Oncotarget 2011; 2:  797 - 809 801 www.impactjournals.com/oncotarget
3 different breast cancer cell lines. In MCF-7 cells, the 
combination of propranolol and paclitaxel resulted in a 
slight antagonism at 1 nM paclitaxel but it became highly 
synergistic with increasing paclitaxel concentrations. 
In contrast, this drug combination led to a sub-additive 
effect  at  all  tested  concentrations  in  MDA-MB-231 
cells and changed from additivity to antagonism with 
increasing  paclitaxel  concentrations  in  SKBR3  cells. 
In BMH29L cells, the combination of propranolol with 
paclitaxel led to a synergistic effect irrespectively of the 
dose of paclitaxel used whereas in HMEC-1 cells, this 
combination was sub-additive, additive and synergistic at 
5, 10 and 25nM paclitaxel, respectively. Finally, mixed 
results were also obtained with the other cancer cell lines 
(Table  1).  In A549,  the  interaction  between  paclitaxel 
and propranolol changed from synergism to antagonism 
with increasing paclitaxel concentration whereas this 
drug combination was synergistic and antagonistic at all 
tested drug concentrations in SK-N-SH and U87 cells, 
respectively. Propranolol thus appeared to modulate the 
anti-proliferative effects of chemotherapy in vitro in a cell 
type-specific and dose-dependent manner.
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Figure 4: In vitro drug combination study of propranolol and 5-fluorouracil on angiogenesis. A) Representative photographs 
of HMEC-1 cells in MatrigelTM assay. Cells were treated 20 min after seeding on MatrigelTM with a range of 5-fluorouracil concentrations 
(0, left panel; 10 μM, middle panel and 50 μM, right panel) in absence (top panel) or presence of propranolol (10 μM, middle panel and 
50 μM, bottom panel) and photographs were taken after 8h drug incubation. Vascular structures were imaged on a Zeiss Axiovert 200M 
using a 5 X objective. Inset, % of inhibition as compared to untreated control cells (N.S = not statistically significant); Scale bar, 200 µm. 
B) Histogram representation of the anti-angiogenic effects of 5-fluorouracil in combination with propranolol. Columns, means of at least 
four individual experiments; bars, SE. Statistical analysis by ANOVA, combination vs 5-FU alone: ** p<0.01; *** p<0.001.Oncotarget 2011; 2:  797 - 809 802 www.impactjournals.com/oncotarget
Propranolol potentiates the anti-angiogenic 
effects of chemotherapy in vitro
To further explore the potential of propranolol 
to enhance the anti-cancer effects of chemotherapy, 
drug  combination  studies  using  MatrigelTM assay were 
performed. As shown in Figure 4, propranolol was able 
to potentiate the anti-angiogenic effects induced by 5-FU. 
While incubation with 10 μM of either drug alone did 
not significantly affect the capacity of HMEC-1 cells to 
form vascular structures, the combination of both drugs 
at this concentration resulted in a small but significant 
inhibition of angiogenesis (-12%; p<0.01) (Figure 4A). 
The  presence  of  10  μM  propranolol  further  increased 
the inhibition of angiogenesis induced by 50 μM 5-FU 
from 19 to 48% (p<0.001). The effect however did not 
dramatically increase when higher concentrations of 
propranolol were used. 
The combination of propranolol and paclitaxel 
appeared to be even more potent at inhibiting angiogenesis 
(Figure  5).  In  the  absence  of  propranolol,  10  and  50 
nM  paclitaxel  inhibited  vascular  structure  formation 
by 44 and 71%, respectively whereas in the presence 
of  10  μM  propranolol  this  increased  to  76  and  92% 
inhibition,  respectively  (p<0.05).  Similar  results  were 
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Figure 5: In vitro drug combination study of propranolol and paclitaxel on angiogenesis. A) Representative photographs 
of HMEC-1 cells in MatrigelTM assay. Cells were treated 20 min after seeding on MatrigelTM with a range of paclitaxel concentrations (0, 
left panel; 10 nM, middle panel and 50 nM, right panel) in absence (top panel) or presence of propranolol (10 μM, middle panel and 50 
μM, bottom panel) and photographs were taken after 8h drug incubation. Vascular structures were imaged on a Zeiss Axiovert 200M using 
a 5 X objective. Inset, % of inhibition as compared to untreated control cells (N.S = not statistically significant); Scale bar, 200 µm. B) 
Histogram representation of the anti-angiogenic effects of paclitaxel in combination with propranolol. Columns, means of at least four 
individual experiments; bars, SE. Statistical analysis by ANOVA, combination vs paclitaxel alone: * p<0.05; ** p<0.01; *** p<0.001.Oncotarget 2011; 2:  797 - 809 803 www.impactjournals.com/oncotarget
obtained  with  BMH29L  cells  (data  not  shown).  Time-
lapse videomicroscopy experiments further confirmed the 
increase in the anti-angiogenic effects of paclitaxel when 
used in combination with propranolol (supplementary 
videos  1-4).  As  compared  to  treatment  with  either 
drug alone, treatment with the combination resulted in 
incomplete morphological differentiation of endothelial 
cells into vascular structures, followed by regression 
of  the  few  structures  formed  (supplementary  video  4). 
Collectively  these  results  demonstrate  that  propranolol 
can significantly potentiate the anti-angiogenic effects of 
chemotherapeutic drugs in vitro.
Propranolol increases the efficacy of chemotherapy 
in a mouse orthotopic model of human triple-
negative breast cancer
To investigate the effect of combining propranolol 
with chemotherapy on tumor growth and survival in vivo, 
a mouse orthotopic model of human triple-negative breast 
cancer was used and the combination of propranolol 
and paclitaxel was evaluated. Treatment consisted of i.p 
injections of paclitaxel alone (20 mg/kg, 3 days a week 
for 3 weeks), propranolol alone (10 mg/kg, 5 days a week 
for 5 weeks) or the combination of both drugs. All three 
treatments were well tolerated as evidenced by an absence 
of weight loss or change in animal well-being as compared 
with vehicle-only treated mice (data not shown). Weekly 
bioluminescence measurements showed that propranolol 
alone did not significantly delay tumor growth, whereas 
treatment with paclitaxel alone or in combination with 
propranolol considerably inhibited tumor progression 
(Figure 6A-B). The addition of propranolol to paclitaxel 
did not significantly increase the very potent anti-tumor 
effects  induced  by  paclitaxel  alone  (Figure  6A-B  and 
supplementary Figure 5). It did however induce significant 
survival benefits as compared to paclitaxel alone (Figure 
6C and Table 2). Median survival was thus increased from 
70 days in animals treated with paclitaxel alone to 125 
days in animals receiving the combination of propranolol 
and paclitaxel. Furthermore, at study completion (150 
days after start of treatment), 12.5% (1/8) and 25% (2/8) of 
mice were tumor-free in the cohorts of animals receiving 
paclitaxel alone and the combination of propranolol and 
paclitaxel, respectively.
Similar results were obtained when combining 
propranolol and 5-FU in vivo (supplementary Figure 6 
and Table 2). The addition of propranolol to 5-FU did 
not significantly increase the anti-tumor effects induced 
by 5-FU alone, except at week 4 of treatment (p<0.05). 
However, this combination appeared to be the most 
effective treatment regimen in terms of survival benefits. 
Indeed, it led to a substantial increase in median survival 
from 44 days for both vehicle-treated and propranolol-
treated mice and 47 days for mice treated with 5-FU alone 
to 56 days for mice treated with the combination. Our 
results thus demonstrate that propranolol can enhance the 
efficacy of chemotherapy in a mouse orthotopic model of 
human triple-negative breast cancer.
DIscUssION
Accumulating  clinical  evidence  suggests  that 
beta-adrenergic receptor antagonists and propranolol in 
particular may lead to increased survival and decreased 
recurrence in breast cancer patients [30-32]. Here, we 
provide the first evidence that propranolol can increase 
the efficacy of chemotherapy, either through direct effects 
on tumor angiogenesis and/or by potentiating the anti-
angiogenic and anti-tumor effects of chemotherapeutic 
drugs. 
Our  study  first  demonstrated  that  propranolol  has 
relatively modest anti-proliferative properties in vitro 
against a panel of 9 human cell lines. High concentrations 
of propranolol were required to significantly inhibit cell 
proliferation, with IC50 values ranging from 100 μM to >250 
μM across the panel of cell lines. Early pharmacokinetics 
studies revealed that clinically relevant concentrations 
of propranolol are in the low μM range [35, 36], thus 
suggesting that propranolol alone is not likely to inhibit 
cell proliferation in vivo. The sensitivity to propranolol 
was cell type specific but did not depend on the tissue of 
origin, since all 4 cell lines of breast tissue origin displayed 
different levels of sensitivity. Interestingly, MCF-7 breast 
cancer cells were twice as much sensitive to propranolol 
than MDA-MB-231 cells, although the former have been 
reported to express low levels of β-ARs as compared to the 
latter [37]. This suggests that the level of β-AR expression 
may  not  directly  influence  cell  sensitivity  to  the  anti-
proliferative effect of propranolol. In contrast with its 
modest effects on cell proliferation, propranolol was able 
to significantly inhibit angiogenesis in vitro at relatively 
low  concentrations  (from  10  and  20  μM  in  BMH29L 
and  HMEC-1  cells,  respectively).  These  results  were 
consistent with those previously reported with other types 
of vascular endothelial cells (i.e. HUVEC and HMVEC) 
[18] and confirmed the potent anti-angiogenic activity of 
propranolol. The current study further showed that unlike 
microtubule-depolymerizing agents [38], propranolol has 
almost no vascular-disrupting activity in addition to its 
anti-angiogenic properties. This result indicates that the 
anti-vascular properties of propranolol reported in various 
pre-clinical and clinical studies [5, 26, 27] are mostly due 
to the inhibition of new capillary tube formation rather 
than the disruption of pre-existing vessels. 
Our  in vitro combination studies revealed that 
low concentrations of propranolol can modulate the 
anti-proliferative effects of chemotherapeutic drugs in 
vitro in a cell type-specific and dose-dependent manner. 
Interestingly, human breast carcinoma and vascular 
endothelial cell lines were among the most responsive Oncotarget 2011; 2:  797 - 809 804 www.impactjournals.com/oncotarget
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Figure 6: In vitro drug combination study of propranolol and paclitaxel. NMRI nude mice were injected with luciferase-
expressing MDA-MB-231 cells into the mammary fat pad and randomized into 4 groups following confirmation of engraftment. Treatment 
was initiated 3 weeks after tumor cell injection and consisted of i.p injection of saline 5 days a week for up to 5 weeks, 10 mg/kg 
propranolol alone 5 days a week for 5 weeks, 20 mg/kg paclitaxel alone 3 days a week for 3 weeks or the combination of propranolol 
and paclitaxel. A) Representative pictures of bioluminescence measurements performed 1 week (top panel), 3 weeks (middle panel) and 
7 weeks (bottom panel) after treatment was initiated. The color scale indicates the signal intensity, which is directly proportional to the 
number of tumor cells. Pictures taken at 6 different wavelengths (i.e.,580 to 630 nm) were next combined for 3D reconstruction and tumor 
size evaluation. B) Quantitative analysis of tumor growth by weekly measurements of luciferase activity in mice treated with saline only 
(black; n=6), propranolol alone (green; n=10), paclitaxel alone (blue; n=8) and the combination of propranolol and paclitaxel (red; n=8). 
Points, average luciferase activity; bars, SE; time is expressed in weeks since start of treatment. C) Kaplan-Meier survival curve; time is 
expressed in days since start of treatment.
Propranolol and Paclitaxel  Propranolol and 5-Fluorouracil
Median survival (d) Log rank test Median survival (d) Log rank test
Control 47 - 44 -
Propranolol 44 0.916 44 0.18
Chemotherapy  70 0.0003 47 0.026
Combination 125 0.0005 56 0.0005
table 2: Median survival of breast tumor-bearing mice. Median survival and log-rank test values as determined from the Kaplan-
Meier survival curves. Time is expressed in days since start of treatment.Oncotarget 2011; 2:  797 - 809 805 www.impactjournals.com/oncotarget
to the combination of propranolol and chemotherapy. 
Consistent  with  our  results,  a  recent  study  has  shown 
that the combination of radiotherapy with propranolol 
in gastric cancer cells in vitro led to an increase in 
radiotherapy-induced  apoptosis  [39].  Elsewhere,  β-AR 
agonists such as epinephrine have been previously 
reported  to  induce  resistance  to  paclitaxel  in  MCF-
7 breast cancer cells [40] and to 5-FU in HT-29 colon 
cancer cells [41] through up-regulation of the ABCB1 
gene. However, these two studies also showed that 
propranolol was unable to prevent epinephrine-induced 
overexpression of ABCB1 and its product P-glycoprotein. 
This not only suggests that the potentiation of the anti-
proliferative effects of 5-FU and paclitaxel by propranolol 
reported in the current study is independent from ABCB1 
up-regulation but also reveals that additional mechanisms, 
yet to be discovered, are involved in the regulation of 
drug sensitivity by β-AR signaling. Based on the high 
sensitivity of vascular endothelial cells to propranolol, we 
hypothesized that propranolol may also potentiate the anti-
angiogenic effects of chemotherapeutic drugs. Our finding 
that combining low concentrations of propranolol with 
5-FU  or  paclitaxel  significantly  increases  angiogenesis 
inhibition  in vitro,  demonstrates  for  the  first  time  that 
propranolol can potentiate the anti-angiogenic properties 
of chemotherapeutic drugs through direct effects on 
endothelial  cells.  Additional  experiments  are  currently 
underway to unravel the mechanisms involved in the 
synergism between propranolol and chemotherapeutic 
drugs against cell proliferation and angiogenesis in 
vitro.  A  number  of  candidates  are  being  considered. 
These  include  cAMP-protein  kinase A  (PKA)  and  Src 
kinase signaling pathways, which are both involved in 
the adrenergic regulation of cancer cell proliferation and 
invasion, as well as the inhibition of VEGF receptor-2 
tyrosine  phosphorylation  and  MMP-9  secretion,  which 
have been shown to mediate the anti-angiogenic effects of 
propranolol in vitro [17, 18, 42, 43].
Triple-negative breast cancer is estimated to 
affect more than 170,000 women worldwide each year 
and  associated  with  a  poor  prognosis  [44].  Effective 
therapeutic options are very limited but β-AR antagonists 
have  been  recently  found  to  be  particularly  beneficial 
in triple-negative breast cancer patients [32]. The 
potentiation of the anti-proliferative and anti-angiogenic 
effects of chemotherapeutic drugs in vitro demonstrated 
in the current study provides two potential mechanisms 
by which propranolol may be able to increase the anti-
tumor efficacy of chemotherapy in vivo. Previous studies 
have found that propranolol could inhibit the development 
of stress-induced metastasis in preclinical models of both 
ovarian and breast cancer but it only affected primary 
tumor growth in the ovarian cancer model [26, 27]. Here 
we found that propranolol alone induced only minor and 
transient anti-tumor effects in a mouse orthotopic model 
of breast cancer and it did not lead to survival benefits. 
This result, together with those previously reported in the 
literature, suggest that the anti-tumor effects of propranolol 
are most likely to occur in small disseminated tumors 
but not in larger, bulky tumors, which is consistent with 
the potent anti-angiogenic but weak vascular-disrupting 
properties of propranolol reported here. Nevertheless, our 
study further showed that, in absence of chronic stress, 
propranolol  can  enhance  the  efficacy  of  chemotherapy 
in vivo. Although the difference did not reach statistical 
significance, there was a clear trend towards a more potent 
anti-tumor effect when propranolol was combined with 
chemotherapy, as compared with chemotherapy alone. 
Furthermore, combining propranolol to chemotherapy 
resulted in improved survival in two independent in 
vivo studies. The addition of propranolol thus increased 
the median survival by 79% and 19% as compared to 
paclitaxel alone and 5-FU alone, respectively.
Collectively,  our  results  indicate  that  propranolol 
could potentially be used concomitantly with 
chemotherapy in breast cancer patients to increase 
treatment efficacy. The evaluation of such combination 
therapy in prospective clinical trials is urgently needed, 
particularly in triple-negative breast cancer patients for 
whom effective therapeutic options are extremely limited. 
If successful, this clinical translation could rapidly impact 
on the treatment of more than 1 million women worldwide 
affected by breast cancer each year, thus further illustrating 
the numerous advantages of drug repositioning in terms of 
time- and cost-saving. Finally, it is also important to note 
that β-AR antagonists could also be beneficial in other 
types of drug-refractory solid tumors and warrants further 
investigation in clinically-relevant models of both adult 
and childhood cancers. 
MAtErIAL AND MEtHODs
reagents
Propranolol (Sigma-Aldrich, Castle Hill, Australia) 
was resuspended in water and stock solutions (50 
mM)  were  stored  at  4°C.  Commercial  solutions  of 
5-fluorouracil in saline were obtained from La Timone 
University  Hospital  of  Marseille,  France  and  Hospira 
Australia (Mulgrave North, Australia) and stored at room 
temperature. Paclitaxel (Sigma-Aldrich) was resuspended 
in  DMSO  and  stock  solutions  (2  mM)  were  stored  at 
-20°C.
cell culture 
The breast cancer cell line MCF-7 and glioblastoma 
cell  line  U87  were  maintained  in  DMEM  medium 
(Invitrogen, Mount Waverley, Australia), the breast cancer 
cell line MDA-MB-231, non-small cell lung cancer cell Oncotarget 2011; 2:  797 - 809 806 www.impactjournals.com/oncotarget
line A549  and  neuroblastoma  cell  line  SK-N-SH  were 
maintained in RPMI-1640 medium (Invitrogen), the breast 
cancer cell line SKBR3 was maintained in McCoy’5A 
medium  (Invitrogen)  and  the  breast  epithelial  cell  line 
HBL-100  was  maintained  in  MEM  (Invitrogen).  All 
these culture media were supplemented with 10% Fetal 
Calf Serum (FCS), 2 mM L-glutamine and 1% penicillin 
streptomycin. The microvascular endothelial cell line 
HMEC-1 was grown on 0.1% gelatin-coated flasks using 
MCDB-131 medium (Invitrogen) containing 10% FCS, 2 
mM L-glutamine, 1% penicillin and streptomycin, 1 μg/
mL hydrocortisone and 10 ng/mL epithelial growth factor 
(BioScientific, Gymea, Australia). BMH29L cells are bone 
marrow derived endothelial cells that were immortalized 
by ectopic expression of human telomerase reverse 
transcriptase [45]. They were kindly provided by Dr 
Karen MacKenzie (Children’s Cancer Institute Australia) 
and grown on 0.1% gelatin-coated flasks using Medium 
199  (Invitrogen)  containing  20%  FCS,  5%  AB-only 
male human serum (Sigma-Aldrich), 1% penicillin and 
streptomycin, 1% heparin, 5 ng/mL recombinant human 
FGFβ  (fibroblast  growth  factor  β;  Sigma-Aldrich)  and 
20 μg/mL Endothelial Cell Growth Factor (Roche, Dee 
Why, Australia). All cell lines were routinely maintained 
in culture at 37°C and 5% CO2 and regularly screened to 
ensure the absence of mycoplasma contamination.
Growth inhibition assay
Growth inhibition assays were performed using 
either Alamar blue (for MCF-7, MDA-MB-231, HMEC-
1 and BMH29L cells) or MTT (for SKBR3, HBL-100, 
A549, SK-N-SH and U87), as previously described [46, 
47]. For all cell lines, the number of cells seeded (from 
1,500 to 10,000 cells per well, depending on the cell line) 
in 96-well plates was first optimized to ensure sustained 
exponential growth for 4-6 days. For all cell lines (with 
the exception of SK-N-SH cells, which were allowed to 
adhere for 72h before treatment was initiated), cells were 
treated 24h after seeding with a range of concentrations 
of  i)  propranolol  alone  (1  x  10-7 to 1 x 10-4  M),  ii) 
chemotherapeutic drugs alone (1 x 10-8 to 5 x 10-4 M and 1 
x 10-11 to 1 x 10-7 M for 5-FU and paclitaxel, respectively) 
or  iii)  chemotherapeutic  drugs  in  combination  with 
propranolol at the lowest effective concentration (IC15). 
After  72h  drug  incubation,  metabolic  activity  was 
detected by addition of Alamar blue or MTT followed 
by  spectrophotometric  analysis.  Cell  proliferation  was 
determined and expressed as a percentage of untreated 
control  cells.  The  determination  of  IC50 values was 
performed using GraphPad Prism 4 software (GraphPad 
Software  Inc,  La  Jolla,  CA).  Combination  index  (CI) 
values were calculated for all tested drug concentrations 
according to the Chou and Talalay method [33, 34] using 
the following equation:
where (D)1 and (D)2 represent the dose of agent 1 and 
2 used in combination to induce X% growth inhibition, 
and (DX)1 and (DX)2 represent the dose of agent 1 and 2 
required to reach X% growth inhibition when used alone. 
The  CI  theorem  then  provides  quantitative  definition 
for  additive  effects  (CI  =  1),  synergisms  (CI<1)  and 
antagonisms (CI>1) in drug combinations.
In vitro MatrigeltM assay
The  MatrigelTM  (BD  Biosciences,  North  Ryde, 
Australia) assay was used to determine the anti-angiogenic 
and vascular-disrupting properties of propranolol alone 
or in combination with chemotherapeutic agents, as 
previously  described  [38].  Briefly,  24-well  plates  were 
coated at 4°C with 270μL of a MatrigelTM solution (1:1 
dilution in cell culture medium), which was then allowed 
to solidify for 1 h at 37°C before cell seeding. For the 
anti-angiogenesis assay, endothelial cells were treated 
with different drug solutions 20 min after seeding on 
MatrigelTM and photographs were taken after 8h drug 
incubation using the 5X objective of an Axiovert 200M 
fluorescent  microscope  coupled  to  an  AxioCamMR3 
camera  driven  by  the  AxioVision  4.7  software  (Carl 
Zeiss, North Ryde, Australia). For the vascular-disruption 
assay,  endothelial  cells  were  first  allowed  to  undergo 
morphogenesis and form capillary-like structures for 
6 h before drug treatment was initiated. Photographs 
were then taken using the same microscope device after 
2h drug incubation. The anti-angiogenic and vascular-
disrupting activities of the compounds were then 
quantitatively evaluated by measuring the total surface 
area of capillary tubes formed in at least 10 view fields 
per  well  using  AxioVision  4.7  software.  Time-lapse 
videomicroscopy was also employed to further evaluate 
the effects of propranolol on the anti-angiogenic activity 
of chemotherapeutic agents, as previously described [38]. 
Cells were constantly maintained at 37°C and 5% CO2 and 
photographs were taken every 5 min from the beginning 
of drug treatment and for 9 h. 
Orthotopic breast cancer model
To evaluate the effect of combining propranolol with 
chemotherapy on tumor growth and survival, 7 weeks-
old NMRI nude mice were injected into the mammary 
fat pad with 50,000 MDA-MB-231-luc-D3H2LN human 
breast cancer cells expressing firefly luciferase (Caliper 
Life Science, Villepinte, France) resuspended in 50 μL 
of  a  30%  MatrigelTM solution.  Mice  were  randomized 
into 4 different groups 18 days after tumor cell injection 
following  confirmation  of  engraftment.  Treatment  was 
𝐶𝐼 = 
𝐷 1
(𝐷𝑋)
1
+
𝐷 2
(𝐷𝑋)
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initiated 3 weeks after injection and consisted of i.p 
injections of i) saline (5 days a week for up to 5 weeks), 
ii)  paclitaxel  alone  (20  mg/kg,  3  days  a  week  for  3 
weeks), iii) propranolol alone (10 mg/kg, 5 days a week 
for  5  weeks)  or  iv)  the  combination  of  paclitaxel  and 
propranolol following the same administration schedule. 
Tumor growth was monitored by weekly bioluminescence 
measurements using the Spectrum IVIS system (Caliper 
Life Science, Villepinte, France). Briefly, light expressed 
as photon/sec was measured 15 minutes after i.p injection 
of 200 mg/kg Luciferine (Caliper Life Science, Villepinte, 
France), a time-lag ensuring the signal to reach a plateau. 
After acquisition, signals were converted into 3D pictures 
using  the  Living  Image  4.2  software  (Caliper  Life 
Science, Villepinte, France). Mice were sacrificed when 
tumor size reached 5,000 mm3 (as determined using a 
vernier caliper and the standard formula tumor volume 
= (thickness x length x width) x π / 6) or when signs of 
morbidity became apparent (e.g., ataxia, signs of pain or 
distress, loss of > 15% of initial weight, loss of mobility 
due to tumor growth).
The  combination  of  propranolol  and  5-FU  was 
also evaluated using the same orthotopic model of 
triple-negative  breast  cancer  with  slight  modifications. 
Briefly,  7  weeks-old  NMRI  nude  mice  were  injected 
into the mammary fat pad with 10,000 MDA-MB-231-
luc-D3H2LN cells in absence of MatrigelTM. Mice were 
randomized into 4 different groups 7 days after tumor 
cell  injection  following  confirmation  of  engraftment. 
Treatment was initiated 2 weeks after injection and 
consisted  of  i.p  injections  of  i)  saline  (5  days  a  week 
for up to 8 weeks), ii) 5-FU alone (30 mg/kg, 3 days a 
week for 5 weeks), iii) propranolol alone (10 mg/kg, 5 
days a week for up to 8 weeks) or iv) the combination of 
5-FU and propranolol following the same administration 
schedule. Tumor growth was monitored by weekly 
bioluminescence measurement using the same protocol 
and device described above. Mice were sacrificed when 
tumor size reached 5,000 mm3 or when signs of morbidity 
became apparent.
statistical analysis
All in vitro experiments were performed at least in 
triplicate and statistical significance was determined using 
two-sided student’s t test and one-way Anova was used 
for multiple comparisons. For in vivo studies, the log rank 
test was used to compare median survival in the different 
treatment groups. All statistical analyses were performed 
using GraphPad Prism 4 (GraphPad Software, Inc).
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sUPPLEMENtAry VIDEOs
Videos 1-4: In vitro angiogenesis assay by time-
lapse  videomicroscopy.  Representative  time-lapse 
videomicroscopy of HMEC-1 cells on MatrigelTM. Cells 
were seeded on MatrigelTM either in the absence of drug 
(video 1) or in the presence of 10 μM propranolol (video 
2), 10 nM paclitaxel (video 3) or a combination of 10 μM 
propranolol and 10 nM paclitaxel (video 4). Photographs 
were taken every 5 min for 9 h, using the 5X objective 
of  an  Axiovert  200M  fluorescent  microscope  coupled 
to  an AxioCamMR3  camera  driven  by  the AxioVision 
4.7 software (Carl Zeiss). The videos together with the 
supplementary figures 5 & 6 can be found online at www.
impactjournals.com/oncotarget
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